Danqi Xinmaikang Attenuates Chronic Heart Failure by Promoting Fatty Acid Oxidation Through Activating AMPK/PGC-1α Signaling Pathway
10.13422/j.cnki.syfjx.20260842
- VernacularTitle:丹芪心脉康激活AMPK/PGC-1α信号通路促进脂肪酸氧化治疗慢性心力衰竭
- Author:
Xiuqin ZHOU
1
;
Yinzhi SONG
1
;
Cuiling LIU
1
;
Zhifang TANG
1
;
Zhongqiu LIU
2
;
Rong ZHANG
2
;
Yuanyuan CHENG
2
;
Qi LIANG
1
Author Information
1. Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518000,China
2. International Institute for Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006,China
- Publication Type:Journal Article
- Keywords:
Danqi Xinmaikang;
chronic heart failure (CHF);
adenosine 5′-monophosphate-activated protein kinase (AMPK) signaling pathway;
fatty acid metabolism;
peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(24):93-103
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effects of Danqi Xinmaikang (DQ) on chronic heart failure (CHF) induced by left anterior descending (LAD) coronary artery ligation in mice and to explore its molecular mechanism of regulating fatty acid oxidation via the adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling pathway to combat CHF. MethodsA CHF model was established in mice by LAD coronary artery ligation. Mice were randomized into sham, model, positive control (sacubitril valsartan sodium tablets 50 mg·kg-1), and low-dose and high-dose DQ groups(0.64,1.28 g·kg-1), with 6 mice in each group. After successful modeling, drug administration was implemented for 4 consecutive weeks. After drug administration, changes in cardiac function parameters such as left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured via cardiac ultrasound. Plasma N-terminal pro-B-type natriuretic peptide precursor (NT-proBNP) levels were determined by enzyme-linked immunosorbent assay (ELISA). Cardiac pathological changes and fibrosis severity were observed via hematoxylin-eosin (HE) staining and Masson staining. Western blot and Real-time quantitative polymerase chain reaction(Real-time PCR) were adopted to determine the protein and mRNA levels, respectively, of AMPK, phosphorylated AMPK (p-AMPK), medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM), carnitine palmitoyltransferase 1A (CPT1A), fatty acid translocase (CD36), and peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α). In vitro experiments employed oxygen-glucose deprivation (OGD) to treat cardiomyocytes, with control, OGD model group, and low-, medium-, and high-dose (1, 3, and 5 g·L-1, respectively) DQ groups established. The expression of relevant molecules in each group was assessed via Western blot and Real-time PCR. AMPK inhibitor Compound C (CC) was further used to verify the role of AMPK pathway in the protective effect of DQ. ResultsCompared with the sham group, the model group exhibited reduced LVEF and LVFS (P<0.05) and an elevated plasma NT-proBNP level (P<0.05), along with significant pathological damage and fibrosis in the myocardial tissue. Compared with the model group, 4 weeks of DQ treatment improved LVEF and LVFS (P<0.05), decreased the plasma NT-proBNP level (P<0.05), and alleviated myocardial fibrosis and pathological damage. In vitro experiments similarly demonstrated that DQ significantly enhanced the cell viability of OGD-treated H9c2 cells compared with the OGD group(P<0.05). Further mechanism studies revealed that DQ, both in vitro and in vivo, promoted AMPK phosphorylation and increased mRNA and protein levels of PGC-1α and fatty acid oxidation-related molecules (ACADM, CPT1A, and CD36) (P<0.05). The AMPK inhibitor Compound C reversed these effects of DQ (P<0.05). ConclusionDanqi Xinmaikang effectively improves the cardiac function in the mouse model of LAD ligation-induced CHF, reduces myocardial injury and fibrosis, and exhibits significant protective effects against OGD-induced cardiomyocyte damage. It activates the AMPK/PGC-1α signaling pathway to promote fatty acid oxidation, thereby ameliorating myocardial energy metabolism disorders. In this study, DQ was associated with ischemic heart failure, providing experimental basis for CHF treatment, suggesting that it has the potential to be a candidate drug for CHF treatment.